Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sanofi (SNY) Other Operating Expenses (2023 - 2026)

Sanofi's Other Operating Expenses history spans 5 years, with the latest figure at -$1.4 billion for Q1 2026.

  • On a quarterly basis, Other Operating Expenses fell 60.15% to -$1.4 billion in Q1 2026 year-over-year; TTM through Mar 2026 was -$10.3 billion, a 88.23% decrease, with the full-year FY2025 number at -$5.1 billion, down 45.81% from a year prior.
  • Other Operating Expenses hit -$1.4 billion in Q1 2026 for Sanofi, up from -$5.1 billion in the prior quarter.
  • Over the last five years, Other Operating Expenses for SNY hit a ceiling of -$656.2 million in Q1 2024 and a floor of -$5.1 billion in Q4 2025.
  • Historically, Other Operating Expenses has averaged -$2.4 billion across 4 years, with a median of -$2.0 billion in 2026.
  • Biggest five-year swings in Other Operating Expenses: plummeted 32.57% in 2024 and later crashed 247.97% in 2025.
  • Tracing SNY's Other Operating Expenses over 4 years: stood at -$2.7 billion in 2023, then plummeted by 32.57% to -$3.5 billion in 2024, then tumbled by 45.81% to -$5.1 billion in 2025, then surged by 72.95% to -$1.4 billion in 2026.
  • Business Quant data shows Other Operating Expenses for SNY at -$1.4 billion in Q1 2026, -$5.1 billion in Q4 2025, and -$3.8 billion in Q3 2025.